Galderma Group AG (SWX:GALD)
158.85
+0.60 (0.38%)
Apr 29, 2026, 12:53 PM CET
Galderma Group AG Revenue
In the year 2025, Galderma Group AG had annual revenue of $5.24B USD with 18.04% growth. Galderma Group AG had revenue of $2.78B in the half year ending December 31, 2025, with 32.02% growth.
Revenue
$5.24B
Revenue Growth
+18.04%
P/S Ratio
8.93
Revenue / Employee
$682.78K
Employees
7,676
Market Cap
37.12B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.24B | 801.00M | 18.04% |
| Dec 31, 2024 | 4.44B | 323.00M | 7.85% |
| Dec 31, 2023 | 4.12B | 293.10M | 7.66% |
| Dec 31, 2022 | 3.82B | 378.90M | 11.00% |
| Dec 31, 2021 | 3.45B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.36B |
| Novartis AG | 44.94B |
| Lonza Group AG | 6.53B |
| Alcon | 8.25B |
| Sandoz Group AG | 8.85B |
| Straumann Holding AG | 2.61B |
| Sonova Holding AG | 3.85B |
| Galenica AG | 4.15B |
Galderma Group AG News
- 5 days ago - Galderma Group AG Earnings Call Transcript: Q1 2026 - Transcripts
- 6 days ago - Galderma Posts Q1 Sales Growth, Confirms FY26 Outlook, Stock Up - Nasdaq
- 6 days ago - Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency - Business Wire
- 6 days ago - Galderma Shareholders Approve All Annual General Meeting Proposals - Business Wire
- 13 days ago - Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform - Business Wire
- 21 days ago - Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare - Business Wire
- 5 weeks ago - AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs - Business Wire
- 5 weeks ago - Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing - Business Wire